Brian T Do
Overview
Explore the profile of Brian T Do including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1765
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abbott K, Subudhi S, Ferreira R, Gultekin Y, Steinbuch S, Munim M, et al.
bioRxiv
. 2024 Nov;
PMID: 39484531
Cancer metastasis is a major contributor to patient morbidity and mortality, yet the factors that determine the organs where cancers can metastasize are incompletely understood. In this study, we quantify...
2.
Sivanand S, Gultekin Y, Winter P, Vermeulen S, Tchourine K, Abbott K, et al.
Nat Metab
. 2024 Aug;
6(9):1668-1681.
PMID: 39160333
Metastases arise from subsets of cancer cells that disseminate from the primary tumour. The ability of cancer cells to thrive in a new tissue site is influenced by genetic and...
3.
Do B, Hsu P, Vermeulen S, Wang Z, Hirz T, Abbott K, et al.
Dev Cell
. 2024 Jun;
59(16):2203-2221.e15.
PMID: 38823395
Control of cellular identity requires coordination of developmental programs with environmental factors such as nutrient availability, suggesting that perturbing metabolism can alter cell state. Here, we find that nucleotide depletion...
4.
Abbott K, Ali A, Casalena D, Do B, Ferreira R, Cheah J, et al.
Cell Chem Biol
. 2023 Sep;
30(9):1156-1168.e7.
PMID: 37689063
A challenge for screening new anticancer drugs is that efficacy in cell culture models is not always predictive of efficacy in patients. One limitation of standard cell culture is a...
5.
Abbott K, Ali A, Casalena D, Do B, Ferreira R, Cheah J, et al.
bioRxiv
. 2023 Mar;
PMID: 36909640
A challenge for screening new candidate drugs to treat cancer is that efficacy in cell culture models is not always predictive of efficacy in patients. One limitation of standard cell...
6.
Do B, Vander Heiden M
Trends Cancer
. 2022 Sep;
8(11):884-886.
PMID: 36153305
To thrive in a hypoxic and nutrient-limited tumor microenvironment, pancreatic ductal adenocarcinoma (PDAC) cells rewire their metabolism. Understanding PDAC cell metabolism may uncover vulnerabilities that can be targeted for improved...
7.
Diehl F, Miettinen T, Elbashir R, Nabel C, Darnell A, Do B, et al.
Nat Cell Biol
. 2022 Aug;
24(8):1252-1264.
PMID: 35927450
Nucleotide metabolism supports RNA synthesis and DNA replication to enable cell growth and division. Nucleotide depletion can inhibit cell growth and proliferation, but how cells sense and respond to changes...
8.
Franklin R, Guo Y, He S, Chen M, Ji F, Zhou X, et al.
Nat Commun
. 2022 Apr;
13(1):2350.
PMID: 35487911
Cell fate commitment is driven by dynamic changes in chromatin architecture and activity of lineage-specific transcription factors (TFs). The chromatin assembly factor-1 (CAF-1) is a histone chaperone that regulates chromatin...
9.
Schwartz A, Goyert J, Solanki S, Kerk S, Chen B, Castillo C, et al.
Nat Metab
. 2021 Jun;
3(7):969-982.
PMID: 34155415
Colorectal cancer (CRC) requires massive iron stores, but the complete mechanisms by which CRC modulates local iron handling are poorly understood. Here, we demonstrate that hepcidin is activated ectopically in...
10.
Reinfeld B, Madden M, Wolf M, Chytil A, Bader J, Patterson A, et al.
Nature
. 2021 Apr;
593(7858):282-288.
PMID: 33828302
Cancer cells characteristically consume glucose through Warburg metabolism, a process that forms the basis of tumour imaging by positron emission tomography (PET). Tumour-infiltrating immune cells also rely on glucose, and...